Harbor Capital Advisors, Inc. Adaptimmune Therapeutics PLC Transaction History

Harbor Capital Advisors, Inc.

  • $1.31 Billion
  • Q2 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024
BUY
$0.7 - $1.75 $28,236 - $70,591
40,338 Added 27.3%
188,070 $297,000
Q4 2023

Jan 08, 2024
BUY
$0.43 - $0.79 $5,726 - $10,520
13,317 Added 9.91%
147,732 $116,000
Q3 2023

Oct 20, 2023
BUY
$0.73 - $1.04 $15,986 - $22,774
21,899 Added 19.46%
134,415 $104,000
Q2 2023

Jul 11, 2023
BUY
$0.9 - $1.51 $101,264 - $169,899
112,516 New
112,516 $103,000

Others Institutions Holding ADAP

# of Institutions
83
Shares Held
160M
Call Options Held
42.8K
Put Options Held
42.1K
View Full List

About Adaptimmune Therapeutics PLC

ADAP Quotes by TradingView
  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $196M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Harbor Capital Advisors, Inc. Portfolio

Follow Harbor Capital Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Harbor Capital Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Harbor Capital Advisors, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email